Loading
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Previous close
$36.65
−$1.15 · -3.04%
Pre-market
$35.65
−$1.00 · -2.73%
Oct 8, 7:31 AM ET
Regular session · ET · Market data may be delayed.
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Day range
Current $36.65
52-week range
Current $36.65
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
76
Undervalued
Sentiment
64
Bullish
Risk
34
Moderate Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Day range
Current $36.65
52-week range
Current $36.65
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.72B USD | 21.53B USD | 16.47B USD | 14.51B USD | 8.42B USD |
| Cost of goods sold | 309.24M USD | 985M USD | 226M USD | — | — |
| Gross profit | 3.41B USD | 20.54B USD | 16.25B USD | 14.51B USD | 8.42B USD |
| Research and development | 1.56B USD | 9.75B USD | 7.63B USD | 5.56B USD | 4.18B USD |
| Selling, general, and administrative | 602.47M USD | 3.79B USD | 3.3B USD | 2.68B USD | 1.28B USD |
| Operating expenses | 2.16B USD | 13.84B USD | 10.93B USD | 8.24B USD | 5.46B USD |
| Interest income | 138.11M USD | 995M USD | 939M USD | 324M USD | 197M USD |
| Interest expense | 61.05M USD | 120M USD | 27M USD | 21M USD | 13M USD |
| Depreciation and amortization | 71.06M USD | 413M USD | 293.62M USD | 362M USD | 248.99M USD |
| Operating income | 1.25B USD | 6.7B USD | 5.32B USD | 6.27B USD | 2.95B USD |
| Net income | 963.76M USD | 7.84B USD | 4.35B USD | 5.45B USD | 2.96B USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$44.75
22.10% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 1, 2018 | 5:1 | — | — |
Effective May 1, 2018
5:1
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB158.43M1.52%10.4B USD0.44%$203.34+0.12%
First Trust NYSE Arca Biotechnology Index FundFBT118.01M4.08%2.89B USD0.55%$263.49-0.56%
Avantis International Equity ETFAVDE18.94M0.10%19.28B USD0.23%$89.48-1.21%
Tema Oncology ETFCANC7.47M3.67%203.21M USD0.99%$40.62+0.40%
Touchstone Dynamic International ETFTDI4.66M0.89%452.51M USD1.04%$46.7204-1.11%
First Trust Nasdaq BuyWrite Income ETFFTQI2.62M0.26%1.01B USD0.75%$22.30-0.22%
Harding Loevner International Developed Markets Select Equity ETFLOEV2.23M2.43%91.47M USD0.70%$15.85-1.02%
John Hancock Investments - Multifactor Developed International ETFJHMD1.95M0.20%980.11M USD0.39%$44.05-1.14%iShares Biotechnology ETFIBBFirst Trust NYSE Arca Biotechnology Index FundFBTAvantis International Equity ETFAVDETema Oncology ETFCANCTouchstone Dynamic International ETFTDIFirst Trust Nasdaq BuyWrite Income ETFFTQIHarding Loevner International Developed Markets Select Equity ETFLOEVJohn Hancock Investments - Multifactor Developed International ETFJHMDAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
